BeiGene receives FDA breakthrough therapy designation for zanubrutinib

BeiGene announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation for its investigational Bruton’s tyrosine kinase inhibitor, zanubrutinib, for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy. “We are very excited to receive the Breakthrough Therapy designation from the FDA,” said Jane Huang, M.D., Chief Medical Officer, Hematology, at BeiGene. “Zanubrutinib has been designed to maximize BTK occupancy and minimize off-target effects. We believe that the Breakthrough Therapy designation underscores the potential of zanubrutinib as a meaningful treatment for patients with MCL who have received at least one prior therapy. More than 1,300 patients worldwide have been treated with zanubrutinib, and it’s being developed in a broad clinical program that currently includes seven Phase 3 or pivotal trials conducted globally or in China.”

https://thefly.com/landingPageNews.php?id=2848516